Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

ALL ENROLLED PARTICIPANTS COMPLETED PHASE III CLINICAL TRIAL OF MT1013

The board of directors (the "**Board**") of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that, all enrolled participants in the Company's pivotal phase III clinical trial of its core product MT1013 have completed study treatment and all protocol-specified follow up, with all participants off-study.

ABOUT MT1013

MT1013 is a dual-targeting receptor agonist polypeptide that adopts an OGP-like structure and simultaneously activates the CaSR and mimics the OGP mechanism. It targets two key pathogenic links of Chronic Kidney Disease-Secondary Hyperparathyroidism ("**CKD-SHPT**")/ CKD-MBD by acting on the CaSR in the parathyroid gland and concurrently on disease-related OGP. MT1013 features a dual mechanism of action combining calcimimetic activity and OGP-mediated bone anabolism. It reduces PTH levels while promoting bone formation, and these two effects act synergistically to normalize calcium and phosphorus metabolism. This distinguishes it from traditional single-target calcimimetics, which directly regulate iPTH but lack a direct pro-osteogenic effect. MT1013 is primarily developed for the treatment of CKD-SHPT, with planned expansion to indications such as CKD-MBD with Osteoporosis and CKD-SHPT not on Dialysis.

ABOUT THE PHASE III CLINICAL TRIAL OF MT1013

The Phase III clinical trial of MT1013 is a multicenter, randomized, double-blind, double-dummy study comparing MT1013 with Cinacalcet in patients with CKD-SHPT undergoing maintenance hemodialysis, aiming to evaluate the safety and efficacy of MT1013. The primary endpoints are the proportions of patients in each group whose serum iPTH levels decrease from baseline by more than 50% and more than 30%, respectively, during the efficacy assessment period (EAP). The study enrolled a total of 435 patients.

As of the date of this announcement, no new major safety signals have been identified based on the available safety monitoring data from the Phase III clinical trial. The overall level of participants discontinuation from the trial has been broadly in line with expectations at the time of trial design. The trial remains blinded, and data verification and final statistical analysis have yet to be completed. The safety and efficacy results of the trial will be set out in the final clinical study report.

ABOUT CKD-SHPT

CKD-SHPT is a common and severe complication in patients with CKD, particularly those with end-stage renal disease receiving dialysis, and represents one of the core manifestations of CKD-mineral and bone disorder. CKD-SHPT may give rise to renal osteodystrophy, vascular and soft tissue calcification and other disorders, clinically manifesting as bone pain, increased bone fragility, pathological fractures, vascular stiffness and increased cardiovascular burden, and significantly increases the risk of adverse cardiovascular events and mortality among affected patients.

As set out in the prospectus of the Company, according to Frost & Sullivan, the prevalence of CKD-SHPT in China grew from 13.0 million in 2020 to 14.0 million in 2025, and is projected to reach 15.0 million by 2030 and 15.9 million by 2035. In terms of market size, the CKD-SHPT market in China is projected to reach RMB5.0 billion by 2030 and RMB13.1 billion by 2035, representing CAGRs of 18.7% and 21.4% respectively during the corresponding periods.

SIGNIFICANCE TO THE GROUP

The last participant has completed all protocol-specified treatment and follow-up visits in the Phase III trial of MT1013, marking a milestone in the Group's clinical development of its core product MT1013. The remaining steps include data cleaning, database lock, unblinding and statistical analysis. If the trial results support the application, the Company plans to submit a new drug application for MT1013 to the National Medical Products Administration. The Company will issue further announcements on material developments in the trial as and when appropriate.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that MT1013 will ultimately be successfully developed and marketed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Dr. Wang Bing
Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 9 November 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.